1. Home
  2. THH vs LITS Comparison

THH vs LITS Comparison

Compare THH & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

THH

TryHard Holdings Limited Ordinary Shares

N/A

Current Price

$0.59

Market Cap

48.0M

Sector

N/A

ML Signal

N/A

LITS

Lite Strategy Inc.

N/A

Current Price

$1.18

Market Cap

40.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
THH
LITS
Founded
2013
2000
Country
Japan
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.0M
40.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
THH
LITS
Price
$0.59
$1.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
716.4K
372.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$305.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.95
52 Week High
$56.26
$3.03

Technical Indicators

Market Signals
Indicator
THH
LITS
Relative Strength Index (RSI) 40.55 51.12
Support Level $0.53 $1.17
Resistance Level $8.42 $1.65
Average True Range (ATR) 0.06 0.09
MACD 0.62 0.02
Stochastic Oscillator 36.72 97.99

Price Performance

Historical Comparison
THH
LITS

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: